Precipio, Inc.
Close on Oct 19, 2026
- Market cap
- $39.12M
- P/E (TTM)
- –
- Dividend yield
- –
About Precipio
Laboratory Analytical Instruments, SIC 3826
Precipio is a healthcare biotechnology company that focuses on cancer diagnostics, particularly hematologic malignancies. The company operates through two complementary divisions: pathology services and products. The pathology services division delivers advanced oncology testing, such as molecular diagnostics and cytogenetics, to physicians, clinics, hospitals, and external laboratories. In parallel, the products division develops and commercializes proprietary diagnostic assays and culture media, including its HemeScreen test panels and IV-Cell media, for use by clinical laboratory customers.
The company operates two clinical laboratories, including a commercial facility in New Haven, Connecticut, and provides diagnostic blood cancer testing to oncology practices across more than 20 U.S. states. In addition to marketing within the United States oncology diagnostics sector, the business distributes proprietary products internationally, including registered sales in Northern Ireland under European medical device transitional rules. The provided text notes operations centered at its New Haven, Connecticut commercial facility, but does not explicitly name a distinct corporate headquarters.
Summary of the business section of Precipio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Precipio, Inc.
- Headquarters
- New Haven, CT
- Address
- 4 Science Park 06511
- Phone
- (203) 787-7888
- Website
- precipiodx.com
- Employees
- 61, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., New Haven, CT
Stock & identifiers
- Ticker
- PRPO
- Exchange
- Nasdaq
- IPO date
- Jun 30, 2017
- Shares outstanding
- 2M, Aug 10, 2026
- Public float
- $15.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Sep 22, 2023; 1-for-20 reverse, Sep 21, 2023; 1-for-15 reverse, Apr 29, 2019; 1-for-15 reverse, Apr 25, 2019; 1-for-51 reverse, Aug 22, 2017; 1-for-12 reverse, Jan 27, 2014
- SEC CIK
- 1043961
- CUSIP
- 74019L602
- ISIN
- US74019L6020
- LEI
- 54930079ULTBRXUQNR89
- EIN
- 91-1789357
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ilan Danieli | Chief Executive Officer, Director | 226,760 |
| Ahmed Zaki Sabet | Chief Operating Officer | 1,034 |
| Matthew Gage | Chief Financial Officer | – |
| Jeffrey Cossman | Director | 16,549 |
| Christina Rizopoulos Valauri | Director | 5,628 |
| David Seth Cohen | Director | 55,199 |
| Richard A. Sandberg | Director | 36,142 |
| Ronald Asbury Andrews | Director | 15,796 |
| Kathleen Laporte | Director | 7,382 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Ilan S. Danieli | $472.72K | $783.58K | $310.41K | $208 | – |
| FY2024 Ilan S. Danieli | $462.10K | $422.29K | $401.23K | $50 | – |
| FY2023 Ilan S. Danieli | $473.44K | $314.07K | $274.92K | $59 | – |
| FY2022 Ilan S. Danieli | $805.10K | $137.94K | $412.34K | $27 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We are a small company with 61 full-time employees and 10 part-time employees as of March 9, 2026.”
Corporate history
Events identified from SEC filings